

Pulmonary Embolism - Pipeline Insight, 2021

<https://marketpublishers.com/r/P86DCF913B5EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P86DCF913B5EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Pulmonary Embolism - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pulmonary Embolism Understanding

Pulmonary Embolism: Overview

Pulmonary embolism (PE) describes a blockage of one of the pulmonary arteries by a blood clot that forms elsewhere in the body and travels to the lung. The symptoms of pulmonary embolism may include pleuritic chest pain, shortness of breath, rapid heart rate, and anxiety. The diagnosis of PE is most often confirmed by lung CT scan or pulmonary angiography. Treatment of pulmonary embolism is aimed at keeping the blood clot from getting bigger and preventing new clots from forming. Prompt treatment is essential to prevent serious complications or death. Anticoagulant medications, such as heparin, enoxaparin, or warfarin are usually given to help thin the blood and prevent further clotting. The major complication of anticoagulation is bleeding.

'Pulmonary Embolism - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Embolism pipeline landscape is provided which includes the disease overview and Pulmonary Embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Embolism.

Pulmonary Embolism Emerging Drugs Chapters

This segment of the Pulmonary Embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Embolism Emerging Drugs

Recombinant staphylokinase: Supergene

Recombinant staphylokinase contains forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.

Recombinant human prourokinase: Tasly Pharmaceuticals

Recombinant human prourokinase is being developed by Tasly Pharmaceuticals, for the treatment of myocardial infarction, stroke and pulmonary embolism. Human pro-urokinase, is a single chain structure urokinase-type plasminogen activator, prepared via recombinant DNA technology. The drug is in Phase II clinical studies for the treatment of pulmonary embolism.

Further product details are provided in the report.....

Pulmonary Embolism: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Embolism drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pulmonary Embolism

There are approx. 5+ key companies which are developing the therapies for Pulmonary Embolism. The companies which have their Pulmonary Embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pulmonary Embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Embolism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Embolism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Embolism drugs.

Pulmonary Embolism Report Insights

- Pulmonary Embolism Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Pulmonary Embolism Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pulmonary Embolism drugs?

How many Pulmonary Embolism drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Embolism?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Embolism therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pulmonary Embolism and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Supergene

Servier

Daiichi Sankyo Company

Tasly Pharmaceuticals

Yuhan

Key Products

Recombinant staphylokinase

S-62798

DS 1040

Recombinant human prourokinase

YHP1906

Contents

Introduction

Executive Summary

Pulmonary Embolism: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Pulmonary Embolism – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Recombinant staphylokinase: Supergene

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Recombinant human prourokinase: Tasly Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

YHP1906: Yuhan

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Pulmonary Embolism Key Companies
Pulmonary Embolism Key Products
Pulmonary Embolism- Unmet Needs
Pulmonary Embolism- Market Drivers and Barriers
Pulmonary Embolism- Future Perspectives and Conclusion
Pulmonary Embolism Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Pulmonary Embolism

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Pulmonary Embolism

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Pulmonary Embolism - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P86DCF913B5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P86DCF913B5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970